Malignant News and Research

RSS

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

Cyterix raises $9.2M in Series A financing from The Column Group and SV Life Sciences

Cyterix Pharmaceutics, Inc. announced today that the company has raised $9.2 million in a Series A financing from The Column Group and SV Life Sciences. Cyterix is developing novel cancer therapeutics based on a prodrug approach that targets extra-hepatic cytochrome P450 enzymes that are over-expressed in many cancers to a high frequency, but not in normal tissues.

7 Jun 2011

Unique clinical trial addresses important questions about treating AIDS-related cancers

As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others.

7 Jun 2011

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).

7 Jun 2011

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

6 Jun 2011

Senescent melanoma cells express an inflammatory secretome

Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In this paper, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile ("secretome") that can ultimately promote metastasis and contribute to melanoma relapse.

6 Jun 2011

EUS-guided GI biopsies with Cook Medical's new, large-core biopsy needle overcomes limitations

Results from a multicenter European study suggest that a new, large-core biopsy needle designed for use with an endoscopic ultrasound (EUS) scope may help to overcome limitations of current EUS methods for biopsies of lesions in the gastrointestinal (GI) tract and surrounding tissue.

6 Jun 2011

Researcher finds thyroid cancer gene inhibits spread of malignant cells

A mutant gene long thought to accelerate tumor growth in thyroid cancer patients actually inhibits the spread of malignant cells, showing promise for novel cancer therapies, a Mayo Clinic study has found.

6 Jun 2011

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Cell Therapeutics, Inc. announced encouraging interim results of a phase II clinical study of OPAXIO combined with temozolomide and radiotherapy in patients with newly diagnosed high-grade malignant brain tumors.

6 Jun 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Survival rates of wealthier patients and those younger than 70 with glioblastoma, the most common and aggressive malignant brain tumor, have improved since 2000, whereas rates for those living in poorer areas and older than 70 have remained stagnant, according to an abstract being presented at the American Society of Clinical Oncology annual meeting in Chicago by Thomas Jefferson University Hospital researchers on Saturday, June 4.

4 Jun 2011

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.

4 Jun 2011

Lung-sparing surgery, photodynamic therapy improve survival of mesothelioma patients

Pleural mesothelioma patients who undergo lung-sparing surgery in combination with photodynamic therapy (PDT) show superior overall survival than patient treated using the conventional therapy of extrapleural pneumonectomy (EPP) with PDT, indicates new research from the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania.

3 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

SGO's Clinical Document outlines expert recommendations for gynecologic cancer surveillance

Although gynecologic cancers account for only 10 percent of all new cancer cases in women, these cancers account for 20 percent of all female cancer survivors. Because long-term survival is now more common, it is increasingly important to detect recurrence.

1 Jun 2011

Type II diabetes drug may slow or stop breast cancer tumor metastasis

A protein activated by certain drugs already approved for treating Type II diabetes may slow or stop the spread of breast tumors.

1 Jun 2011

Cell phones and cancer – link established

In its latest announcement the World Health Organization (WHO) said that radiation from cell phones can possibly cause cancer. According to the WHO's International Agency for Research on Cancer (IARC), radiofrequency electromagnetic fields have been classified as possibly carcinogenic to humans (group 2B) on the basis of an increased risk for glioma that some studies have associated with the use of wireless phones.

1 Jun 2011

New insights into pathogenesis and treatment of hereditary breast, ovarian cancer

5% to 10% of all breast cancers are monogenic in origin. In other words, there is a mutation of the genes BRCA1, BRCA2 or other high-risk genes. In this edition of Deutsches Ärzteblatt International, Alfons Meindl of the Klinikum rechts der Isar and coauthors report on new insights into the pathogenesis and treatment of hereditary breast and ovarian cancer and newly-discovered risk genes.

30 May 2011

D3 Oncology Solutions provides six-month free trial period for Via Oncology Pathways program

D3 Oncology Solutions today announced that it will provide its Via Oncology Pathways for a six-month free trial period to enable cancer programs to align the timing of their investment with a strategy for sharing potential savings with payors and other key stakeholders.

27 May 2011

OVA1 more effective than CA 125 test in evaluating likelihood of ovarian cancer

A paper published in the June issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than a physician's preoperative assessment alone.

From Quest Diagnostics 27 May 2011

Malignant News and Research

NYU Cancer Institute scientists present new research findings at ASCO 2011

Cyterix raises $9.2M in Series A financing from The Column Group and SV Life Sciences

Unique clinical trial addresses important questions about treating AIDS-related cancers

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Senescent melanoma cells express an inflammatory secretome

EUS-guided GI biopsies with Cook Medical's new, large-core biopsy needle overcomes limitations

Researcher finds thyroid cancer gene inhibits spread of malignant cells

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Lung-sparing surgery, photodynamic therapy improve survival of mesothelioma patients

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

SGO's Clinical Document outlines expert recommendations for gynecologic cancer surveillance

Type II diabetes drug may slow or stop breast cancer tumor metastasis

Cell phones and cancer – link established

New insights into pathogenesis and treatment of hereditary breast, ovarian cancer

D3 Oncology Solutions provides six-month free trial period for Via Oncology Pathways program

OVA1 more effective than CA 125 test in evaluating likelihood of ovarian cancer

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News